NCT01147536View on ClinicalTrials.gov

Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence

PHASE2TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Renal Cell Carcinoma
Interventions
BIOLOGICAL

HSPPC-96

Trial Locations (3)

12208

Community Care Physicians, Albany

77030

MD Anderson Cancer Center, Houston

G1R 2J6

Pavillion de Recherche de Hotel Dieu, Québec

Sponsors

Lead Sponsor

Agenus Inc.
All Listed Sponsors
lead

Agenus Inc.

INDUSTRY